comparemela.com
Home
Live Updates
CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies : comparemela.com
CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies
/PRNewswire/ -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for degenerative diseases of the brain, announced an...
Related Keywords
Netherlands
,
United Kingdom
,
Boston
,
Massachusetts
,
United States
,
Spain
,
Barcelona
,
Comunidad Autonoma De Cataluna
,
John Alam
,
Niels Prins
,
Prnewswire Cervomed Inc
,
Pharma Inc
,
Brain Research Center
,
Diffusion Pharmaceuticals Inc
,
International Conference On Alzheimer
,
Nasdaq
,
Twitter
,
Cervomed Inc
,
Linkedin
,
Clinical Dementia Rating Sum Of Boxes
,
Chief Executive Officer
,
Clinical Trials
,
Clinical Dementia Rating Sum
,
Neuropsychological Test Battery
,
International Conference
,
Psychological Medicine
,
Lewy Bodies
,
National Institutes
,
National Institute
,
Diffusion Pharmaceuticals
,
Medical Equipment
,
Health Care Amp Hospitals
,
Medical Pharmaceuticals
,
Biotechnology
,
Clinical Trials Amp Medical Discoveries
,
comparemela.com © 2020. All Rights Reserved.